EPIRUS Biopharmaceuticals, Inc. — Revenue by Fiscal Year
5 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/6ae1ea80-3b30-4be9-8ec1-b9a00cfbd615/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2013 | $14.7M | 2013-01-01 – 2013-12-31 | evidence 0001193125-14-098834 |
| FY 2012 | $12.6M | 2012-01-01 – 2012-12-31 | evidence 0001193125-13-096030 |
| FY 2011 | $8.2M | 2011-01-01 – 2011-12-31 | evidence 0001193125-12-106018 |
| FY 2010 | $46.7M | 2010-01-01 – 2010-12-31 | evidence 0001193125-12-106018 |
| FY 2009 | $17.3M | 2009-01-01 – 2009-12-31 | evidence 0001193125-12-106018 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
EPIRUS Biopharmaceuticals, Inc. — all facts · Net Income · Operating Income